SEC Filings Government Disclosures Contracts + Permits Earnings + IPOs Treasury Yields ETF Explorer Short Volume Screener Stock Research Portfolio Lab

Privacy Policy Terms of Service About

GLMD

Nasdaq

Galmed Pharmaceuticals Ltd.

Market Cap

—

Sector

—

Industry

—

Exchange

Nasdaq

Price Chart

Loading…

Signals

Insider Velocity

News

8

recent articles

No financial data available for GLMD.

Company may not file with SEC or CIK is unresolved.

No Form 4 transactions on record.

Recent News

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Yahoo Finance · 2026-06-08

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

Yahoo Finance · 2026-06-02

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Yahoo Finance · 2026-05-14

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

Informational purposes only, not investment advice.

Yahoo Finance · 2026-05-06

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Yahoo Finance · 2026-04-14

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Yahoo Finance · 2026-04-09

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Yahoo Finance · 2026-03-31

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Yahoo Finance · 2026-01-30